Safety Public Assessment Reports

How Safety Public Assessment Reports work

The Safety Public Assessment Reports (PARs) cover medicines safety issues assessed at a national level by the Commission on Human Medicines (CHM) or its advisory groups. We prioritise the publication of PARs that relate to major national regulatory action.

The reports show the evidence that was available at the time we made the regulatory decision, showing a ‘snapshot’ of the clinical landscape at the time. They are not intended to provide clinical advice.

Since 2012, most safety issues are assessed at an EU level. Reports for these issues can be found on the European Medicines Agency (EMA) or Head of Medicines Agency websites.

We publish updates and prescribing updates on a wide range of medicines in our monthly Drug Safety Update

Reboxetine review of benefits and risks (PDF, 116 KB, 16 pages) (14 September 2011)

Warfarin changes to safety information (PDF, 157 KB, 19 pages) (3 December 2009)

Finasteride risk of male breast cancer (PDF, 288 KB, 27 pages) (3 December 2009)

Recombinant human erythropoietins (epoetins): new prescribing advice (01 December 2007)

Neuroleptics and cardiac safety (PDF, 59.2 KB, 5 pages) (1 July 2006)